

**Supplementary Table S4. Pathologic axillary node status stratified by clinical stage and molecular subtype between patients with breast pathological complete remission (pCR) (ypT0) and non-pCR Response in breast**

	pCR		non-pCR	
	ypN0 (N, %)	ypN+ (N, %)	ypN0 (N, %)	ypN+ (N, %)
Whole population	225(78.4)	62(21.6)	692(40.4)	1020(59.6)
cT1-2N0	55(94.8)	3(5.2)	290(72.7)	109(27.3)
cT1-2N1	118(78.7)	32(21.3)	233(31.7)	501(68.3)
LABC	52(65.8)	27(34.2)	169(29.2)	410(70.8)
Luminal A-like	5(55.6)	4(44.4)	41(38.7)	65(61.3)
cT1-2N0	4(80.0)	1(20.0)	21(75.0)	7(25.0)
cT1-2N1	1(25.0)	3(75.0)	14(31.1)	31(68.9)
LABC	0	0	6(18.2)	27(81.8)
Luminal B-like (HER2-)	76(78.4)	21(21.6)	256(33.6)	506(66.4)
cT1-2N0	18(94.7)	1(5.3)	100(61.7)	62(38.3)
cT1-2N1	44(83.0)	9(17.0)	90(26.1)	255(73.9)
LABC	14(56.0)	11(44.0)	66(25.9)	189(74.1)
Luminal B-like (HER2+)	57(85.1)	10(14.9)	172(46.5)	198(53.5)
cT1-2N0	12(100.0)	0(0.0)	77(84.6)	44(15.4)
cT1-2N1	31(86.1)	5(13.9)	58(36.3)	102(63.7)
LABC	14(73.7)	5(26.3)	37(31.1)	82(68.9)
HER2-amplified	42(85.7)	7(14.3)	121(51.9)	112(48.1)
cT1-2N0	9(100.0)	0(0.0)	47(83.9)	9(16.1)
cT1-2N1	19(82.6)	4(17.4)	38(44.7)	47(55.3)
LABC	14(82.4)	3(17.6)	36(39.1)	56(60.9)
TNBC	45(69.2)	20(30.8)	102(42.3)	139(57.7)
cT1-2N0	12(92.3)	1(7.7)	45(72.6)	17(27.4)
cT1-2N1	23(67.6)	11(32.4)	33(33.3)	66(66.7)
LABC	10(55.6)	8(44.4)	24(30.0)	56(70.0)

Abbreviations: LABC, locally advanced breast cancer; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; pCR, pathological complete remission.